ARTICLE | Clinical News
Orathecin rubitecan regulatory update
July 5, 2004 7:00 AM UTC
SUPG subsidiary EuroGen Pharmaceuticals Ltd. submitted an MAA to the EMEA for Orathecin rubitecan to treat pancreatic cancer in patients who have failed at least one prior chemotherapy regimen. The or...